Cardiac and non-cardiac manifestations of infection caused by group A β-hemolytic Streptococcus
DOI: 10.32364/2618-8430-2022-5-1-63-71
G.V. Santalova, P.A. Lebedev, A.A. Garanin, A.V. Lyamin, M.E. Kuzin
Samara State Medical University, Samara, Russian Federation
Infection caused by group A β-hemolytic Streptococcus (GABHS) is characterized by significant diversity of clinical presentations accounted for by different GABHS strains and individual patients’ predisposition to immune inflammation. This paper reviews current data on streptococcal infection and poststreptococcal cardiac and non-cardiac complications and describes early diagnostic tools. Superficial infections are the most common forms (particularly in pediatrics) manifested as pharyngitis, tonsillitis, otitis, or sinusitis. Invasive infections (pneumonia, necrotizing fasciitis) are potentially lethal conditions accompanied by bacteremia and generalized inflammation. Strains producing exotoxins (GABHS superantigens) provoke scarlet fever and streptococcal toxic shock syndrome. The primary burden of cardiac complications of GABHS infections is still chronic rheumatic heart disease resulting from undiagnosed and untreated acute rheumatic fever. Val vulitis underlying cardiac complications have a subclinical course, requiring echocardiography to establish the diagnosis. Antibacterial treatment with β-lactam antibiotics as a first-line treatment for GABHS infection and prevention of cardiac and non-cardiac complications increase the relevance of early etiological diagnosis. These tools are clinical syndrome scale, culture, and rapid diagnostic tests based on streptococcal DNA and antigen detection.
Keywords: group A β-hemolytic Streptococcus, manifestations and complications of streptococcal infections, acute rheumatic fever, chronic rheumatic heart disease.
For citation: Santalova G.V., Lebedev P.A., Garanin A.A. et al. Cardiac and non-cardiac manifestations of infection caused by group A β-hemolytic Streptococcus. Russian Journal of Woman and Child Health. 2022;5(1):63–71 (in Russ.). DOI: 10.32364/2618-8430-2022-5-1-63-71.
About the authors:
Galina V. Santalova — Dr. Sc. (Med.), Professor, Head of the Department of Faculty Pediatrics, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0002-6078-2361.
Petr A. Lebedev — Dr. Sc. (Med.), Professor, Head of the Department of Therapy of the Institute of Professional Education, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0003-3501-2354.
Andrey A. Garanin — C. Sc. (Med.), assistant of the Department of Propedeutic Therapy, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0001-6665-1533.
Artem A. Lyamin — Dr. Sc. (Med.), Associate Professor, associate professor of the Department of General and Clinical Microbiology, Immunology, and Allergology, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0002-5905-1895.
Maxim E. Kuzin — resident of the Department of Faculty Pediatrics, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0003-4656-3995.
Contact information: Andrey A. Garanin, e-mail: sameagle@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 30.07.2021.
Revised 24.08.2021.
Accepted 16.09.2021.
2. Aksenova A.V., Abeldyaev D.V., Glushkova E.V. Epidemiological aspects of streptococcal and post-streptococcal diseases in the Russian Federation at the present stage. Clinician. 2020;14(1–2):14–23 (in Russ.). DOI: 10.17650/1818-8338-2020-14-1-2-14-23.
3. Chen M., Yao W., Wang X. et al. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China. Pediatr Infect Dis J. 2012;31(9):e158–162. DOI: 10.1097/INF.0b013e31825874f3.
4. Guy R., Williams C., Irvine N. et al. Increase in scarlet fever notifications in the United Kingdom, 2013/2014. Euro Surveill. 2014;19(12):20749. DOI: 10.2807/1560-7917.es2014.19.12.20749.
5. Briko N.I., Glushkova E.V. The state and trends of the epidemic situation of streptococcal (group A) infection in Russia in recent years. Journal of Microbiology, Epidemiology and Immunobiology. 2018;1:10–16 (in Russ.). DOI: 10.36233/0372-9311-2018-1-10-16.
6. Belov B.S. Diagnosis and rational antibacterial therapy of A-streptococcal infections of the pharynx as the basis for primary prevention of acute rheumatic fever. Meditsinskiy Sovet. 2016;4:56–63 (in Russ.). DOI: 10.21518/2079-701X-2016-4-56-63.
7. Mustafa Z., Ghaffari M. Diagnostic Methods, Clinical Guidelines, and Antibiotic Treatment for Group A Streptococcal Pharyngitis: A Narrative Review. Front Cell Infect Microbiol. 2020;10:563627. DOI: 10.3389/fcimb.2020.563627.
8. McIsaac W.J., Goel V., To T., Low D.E. The validity of a sore throat score in family practice. CMAJ. 2000;163(7):811–815.
9. Clinical laboratory diagnostics: national guidelines. Vol. 2. Edited by V.V. Dolgov, V.V. Menshikov. M.: GEOTAR-Media; 2013 (in Russ.).
10. Manual of Medical Microbiology: a study guide. Ed. Labinskaya A.S., Kostyukova N.N., Ivanova S.M. Private medical microbiology and etiological diagnostics of infections. M.: BINOM; 2010 (in Russ.).
11. Manual of clinical microbiology. Ed. J.H. Jorgensen, M.A. Pfaller, K.C. Carroll. 11th ed. Washington: ASM Press; 2015.
12. Otlu B., Karakurt C., Bayındır Y. et al. Carriage of Streptococcus pyogenes in primary school children: M-protein types, pyrogenic toxin genes, and investigation of the clonal relationships between the isolates. Mikrobiyol Bul. 2015;49(3):301–313. DOI: 10.5578/mb.9311.
13. Stevens D.L., Bryant A.E. Severe Group A Streptococcal Infections. In: Ferretti J.J., Stevens D.L., Fischetti V.A., eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016.
14. Teatero S., McGeer A., Tyrrell G.J. et al. Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease. Open Forum Infect Dis. 2018;5(5):ofy085. DOI: 10.1093/ofid/ofy085.
15. Popescu C., Leuştean A., Orfanu A.E. et al. Neutropenia and T-Wave Inversion as Toxin-Mediated Complications of a Streptococcal Infection. J Crit Care Med (Targu Mures). 2017;3(4):166–171. DOI: 10.1515/jccm-2017-0030.
16. Van den Boogaard J., Hahne S.J., Te Wierik M.J. et al. Out-of-season increase of puerperal fever with group A Streptococcus infection: a case-control study, Netherlands, July to August 2018. Euro Surveill. 2020;25(40):1900589. DOI: 10.2807/1560-7917.ES.2020.25.40.1900589.
17. Meskina E.R., Khadisova M.K. Invasive streptococcal group A infection in children: a review of the literature and a clinical case of the toxic shock syndrome and complicated community-acquired pneumonia in a child with a lung malformation. Al’manakh klinicheskoy meditsiny. 2018;46(2):171–183 (in Russ.). DOI: 10.18786/2072-0505-2018-46-2-171-183.
18. Centers for Disease Control and Prevention. 2015. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group A Streptococcus; 2015.
19. Krasnova E.I. Streptococcal infection. Clinical and diagnostic, therapeutic and preventive aspects. Novosibirsk: Sibmedizdat NSMU; 2015 (in Russ.).
20. Imöhl M., Fitzner C., Perniciaro S. et al. Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014. PLoS One. 2017;12(7):e0180757. DOI: 10.1371/journal.pone.0180757.
21. Schwartz B., Facklam R.R., Breiman R.F. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336(8724):1167–1171. DOI: 10.1016/0140-6736(90)92777-f.
22. Oppegaard O., Mylvaganam H., Kittang B.R. Beta-haemolytic group A, C and G streptococcal infections in Western Norway: a 15-year retrospective survey. Clin Microbiol Infect. 2015;21(2):171–178. DOI: 10.1016/j.cmi.2014.08.019.
23. Spaulding A.R., Salgado-Pabón W., Kohler P.L. et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013;26(3):422–447. DOI: 10.1128/CMR.00104-12.
24. Schlievert P.M., Bohach G.A. Staphylococcal and streptococcal superantigens: an update. In: Kotb M., Fraser J.D., eds. Superantigens: molecular basis for their role in human diseases. Washington: ASM Press; 2007.
25. Andrade D.C., Borges I.C., Vilas-Boas A.L. et al. Infection by Streptococcus pneumoniae in children with or without radiologically confirmed pneumonia. J Pediatr (Rio J). 2018;94(1):23–30. DOI: 10.1016/j.jped.2017.03.004.
26. Lamagni T., Guy R., Chand M. et al Resurgence of scarlet fever in England, 2014–16: a population-based surveillance study. Lancet Infect Dis. 2018;18(2):180–187. DOI: 10.1016/S1473-3099(17)30693-X.
27. Park D.W., Kim S.H., Park J.W. et al. Incidence and Characteristics of Scarlet Fever, South Korea, 2008–2015. Emerg Infect Dis. 2017;23(4):658–661. DOI: 10.3201/eid2304.160773.
28. Balasubramanian R., Marks S.D. Post-infectious glomerulonephritis. Paediatr Int Child Health. 2017;37(4):240–247. DOI: 10.1080/20469047.2017.1369642.
29. Rodriguez-Iturbe B., Haas M. Post-Streptococcal Glomerulonephritis. In: Ferretti J.J., Stevens D.L., Fischetti V.A., eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016.
30. VanDeVoorde R.G. 3rd. Acute poststreptococcal glomerulonephritis: the most common acute glomerulonephritis. Pediatr Rev. 2015;36(1):3–12. DOI: 10.1542/pir.36-1-3.
31. Kasahara T., Hayakawa H., Okubo S. et al. Prognosis of acute poststreptococcal glomerulonephritis (APSGN) is excellent in children, when adequately diagnosed. Pediatr Int. 2001;43(4):364–367. DOI: 10.1046/j.1442-200x.2001.01410.x.
32. Rawla P., Padala S.A., Ludhwani D. Poststreptococcal Glomerulonephritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 30855843.
33. Maness D.L., Martin M., Mitchell G. Poststreptococcal Illness: Recognition and Management. Am Fam Physician. 2018;97(8):517–522.
34. Martin W.J., Steer A.C., Smeesters P.R. et al. Post-infectious group A streptococcal autoimmune syndromes and the heart. Autoimmun Rev. 2015;14(8):710–725. DOI: 10.1016/j.autrev.2015.04.005.
35. Farhood Z., Ong A.A., Discolo C.M. PANDAS: A systematic review of treatment options. Int J Pediatr Otorhinolaryngol. 2016;89:149–153. DOI: 10.1016/j.ijporl.2016.08.008.
36. Kostik I.A., Kostik M.M. Current approaches to PANS/PANDAS diagnosis and management. Voprosy Sovremennoi Pediatrii. 2019;18(5):324–338 (in Russ.). DOI: 10.15690/vsp.v18i5.2055.
37. Watkins D.A., Johnson C.O., Colquhoun S.M. et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. N Engl J Med. 2017;377(8):713–722. DOI: 10.1056/NEJMoa1603693.
38. Animasahun B.A., Madise Wobo A.D., Itiola A.Y. et al. The burden of rheumatic heart disease among children in Lagos: how are we fairing? Pan Afr Med J. 2018;29:150. DOI: 10.11604/pamj.2018.29.150.12603.
39. Belov B.S. Group a streptococcal pharyngeal infections: diagnosis and rational antibacterial therapy. Antibiotiki i khimioterapiya. 2018;63(5–6):68–75 (in Russ.).
40. Roberts K., Maguire G., Brown A. et al. Echocardiographic screening for rheumatic heart disease in high and low risk Australian children. Circulation. 2014;129(19):1953–1961. DOI: 10.1161/CIRCULATIONAHA.113.003495.
41. Zühlke L., Karthikeyan G., Engel M.E. et al. Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study). Circulation. 2016;134(19):1456–1466. DOI: 10.1161/CIRCULATIONAHA.116.024769.
42. Nascimento B.R., Beaton A.Z., Nunes M.C. et al. Echocardiographic prevalence of rheumatic heart disease in Brazilian schoolchildren: Data from the PROVAR study. Int J Cardiol. 2016;219:439–445. DOI: 10.1016/j.ijcard.2016.06.088.
43. Ribeiro A.L., Duncan B.B., Brant L.C. et al. Cardiovascular Health in Brazil: Trends and Perspectives. Circulation. 2016;133(4):422–433. DOI: 10.1161/CIRCULATIONAHA.114.008727.
44. Engelman D., Wheaton G.R., Mataika R.L. et al. Screening-detected rheumatic heart disease can progress to severe disease. Heart Asia. 2016;8(2):67–73. DOI: 10.1136/heartasia-2016-010847.
45. Leal M.T., Passos L.S., Guarçoni F.V. et al. Rheumatic heart disease in the modern era: recent developments and current challenges. Rev Soc Bras Med Trop. 2019;52:e20180041. DOI: 10.1590/0037-8682-0041-2019.
46. Zühlke L., Mayosi B.M. Echocardiographic screening for subclinical rheumatic heart disease remains a research tool pending studies of impact on prognosis. Curr Cardiol Rep. 2013;15(3):343. DOI: 10.1007/s11886-012-0343-1.
47. Saxena A., Zuhlke L., Wilson N. Echocardiographic screening for rheumatic heart disease: Issues for the cardiology community. Glob Heart. 2013;8(3):197–202. DOI: 10.1016/j.gheart.2013.08.004.
48. Roberts K., Colquhoun S., Steer A. et al. Screening for rheumatic heart disease: current approaches and controversies. Nat Rev Cardiol. 2013;10(1):49–58. DOI: 10.1038/nrcardio.2012.157.
49. Reményi B., Wilson N., Steer A. et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease-an evidence-based guideline. Nat Rev Cardiol. 2012;28;9(5):297–309. DOI: 10.1038/nrcardio.2012.7.
50. Rothenbühler M., O’Sullivan C.J., Stortecky S. et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. Lancet Glob Health. 2014;2(12):e717–726. DOI: 10.1016/S2214-109X(14)70310-9.
51. Watkins D.A., Beaton A.Z., Carapetis J.R. et al. Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(12):1397–1416. DOI: 10.1016/j.jacc.2018.06.063.
52. Beaton A., Aliku T., Dewyer A. et al. Latent Rheumatic Heart Disease: Identifying the Children at Highest Risk of Unfavorable Outcome. Circulation. 2017;136(23):2233–2244. DOI: 10.1161/CIRCULATIONAHA.117.029936.
53. Karthikeyan G. Measuring and reporting disease progression in subclinical rheumatic heart disease. Heart Asia. 2016;8(2):74–75. DOI: 10.1136/heartasia-2016-010857.
54. Cannon J., Roberts K., Milne C., Carapetis J.R. Rheumatic Heart Disease Severity, Progression and Outcomes: A Multi-State Model. J Am Heart Assoc. 2017;6(3):e003498. DOI: 10.1161/JAHA.116.003498.
55. Zühlke L., Engel M.E., Lemmer C.E. et al. The natural history of latent rheumatic heart disease in a 5 year follow-up study: a prospective observational study. BMC Cardiovasc Disord. 2016;16:46. DOI: 10.1186/s12872-016-0225-3.
56. White A. WHO Resolution on rheumatic heart disease. Eur Heart J. 2018;39(48):4233. DOI: 10.1093/eurheartj/ehy764.
57. Pastore S., De Cunto A., Benettoni A. et al. The resurgence of rheumatic fever in a developed country area: the role of echocardiography. Rheumatology (Oxford). 2011;50(2):396–400. DOI: 10.1093/rheumatology/keq290.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
